ATS 2018 International Conference - Mobile

Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for Delivering Optimal Pulmonary Dose [Board No. P1326]

Location: Board no. P1326

Session Type: Thematic Poster Session

Monday

May

21

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Roger Causon

PhD
Verona Pharma

Brian T. Maurer

MS
Verona Pharma, plc

John Ayrton

PhD
Verona Pharma

Melodie Armstrong

MD
Quintiles IMS

Kenneth B. Newman

MD
Verona Pharma

View Abstract

Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for Delivering Optimal Pulmonary Dose

Parent Sessions

B33 - COPD: MAINTENANCE THERAPY
05-21-2018 9:15 AM - 4:15 PM